FDA Panel Gives the Green Light for More Anti-NGF Testing

The US FDA has agreed to resume clinical trials with anti-nerve growth (NGF) drugs despite cases of side effects stating the risk-benefit profile indicated a role for their ongoing development. The drugs are being developed for the treatment of a variety of chronic painful conditions, including diabetic peripheral neuropathy.  READ MORE

Source: Medscape

Join us in improving the lives of peripheral neuropathy patients.
Send this to a friend